Ovid Therapeutics Inc — Quarterly Cash Flow (NASDAQ:OVID) | MetaTrader

Open full chart

Financials

Overview Finanzbericht Statistics Dividends

Quarterly Annual

Total assets 102.65 M92.17 M81.65 M77.43 M63.85 M Total liabilities 26.36 M23.94 M22.38 M21.64 M19.15 M Total equity 76.29 M68.23 M59.28 M55.79 M44.7 M Total liabilities & shareholders' equities 102.65 M92.17 M81.65 M77.43 M63.85 M Total debt ————— Net debt —————

Nachrichten

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

Ovid Therapeutics: Bullish Post-PIPE With Two Differentiated CNS Moonshots

Ovid Therapeutics: Wie das Fair-Value-Modell von InvestingPro ein Kurspotenzial von 71 % aufdeckte

Ovid’s KCC2 activator shows promising safety in early trial

Ovid Therapeutics: Aktionäre genehmigen Erhöhung der genehmigten Aktien und weitere Anträge

Ovid Therapeutics shareholders approve increase in authorized shares and related proposals

Roth/MKM stuft Ovid Therapeutics mit "Buy" ein – Aktie mit hohem Kurspotenzial dank Epilepsie-Medikament

Roth/MKM initiates Ovid Therapeutics stock with Buy rating on epilepsy drug

Ovid Therapeutics beruft Petra Kaufmann zur neuen Chief Medical Officer

Ovid Therapeutics appoints Petra Kaufmann as chief medical officer

This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Adverum Biotechnologies (NASDAQ:ADVM), Alto Neuroscience (NYSE:ANRO)

Ovid Therapeutics: EPS verfehlt Schätzungen um 0,02 $ - Umsatz schlechter als erwartet